Photo via CBS News

FDA warns of rare vision-loss side effect from GLP-1 drugs

Read the original at CBS News ↗
Cite

Temko, S. (2026, November 10). FDA warns of rare vision-loss side effect from GLP-1 drugs. CBS News. https://www.cbsnews.com/news/glp-1-vision-loss-side-effect-warning-fda/

Dated from the outlet's own feed. Check the original for its byline.

CBS News · collected 2026-11-10 · by Sandra Temko

Quick Summary

The U.S. Food and Drug Administration (FDA) has issued a new warning about a rare but serious side effect associated with GLP-1 drugs, including popular brands like Ozempic and Wegovy. This warning alerts users to the risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. The FDA’s decision follows an analysis of clinical trials involving more than 125 studies, revealing that approximately six cases per 100,000 patients experienced NAION after a year of GLP-1 use, compared to less than four cases among those on placebo or other glucose-lowering medications.
Written by AI on 2026-11-10, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

The U.S. Food and Drug Administration (FDA) has ordered makers of popular weight-loss GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and permanent vision loss. The FDA announced on November 9, 2026, that the new warning follows research linking GLP-1 drugs to an increased risk of NAION, where patients may experience painless vision loss in one eye upon waking. This condition affects the optic nerve and can result in significant vision impairment or blindness. While some studies indicate a potential link between these drugs and NAION, more research is needed to fully understand the relationship, especially considering that many patients with risk factors for NAION might already have conditions like diabetes or obesity before starting GLP-1 therapy.

Written for “FDA Warns GLP-1 Drugs Eye Risk” on 2026-11-21, grounded in this article and the 11 other(s) covering the same event.

How they differ

8 outlets covered “FDA Warns GLP-1 Drugs Eye Risk”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

CBS NewsThis outlet10 Nov

The U.S. Food and Drug Administration (FDA) has issued a new warning about a rare but serious side effect associated with GLP-1 drugs, including popular brands like Ozempic and Wegovy. This warning alerts users to the risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. The FDA’s decision follows an analysis of clinical trials involving more than 125 studies…

FDA warns of rare vision-loss side effect from GLP-1 drugs (this article)4 articles from CBS News on this story
The Independent10 Nov

The U.S. Food and Drug Administration has required manufacturers of weight-loss drugs like Ozempic and Wegovy to include warnings about a rare eye condition called NAION that can lead to permanent vision loss. The FDA’s decision, made after reviewing reports from over 134,000 patients, found an increased risk of six cases per 100,000 people annually for those taking GLP-1 drugs compared to about four cases among…

Weight loss drugs linked to new rare side effect as new warning labels required →2 articles from The Independent on this story
NBC News9 Nov

The Food and Drug Administration has mandated that manufacturers of GLP-1 drugs, such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION) which can cause sudden blindness. This decision follows research indicating an increased risk of NAION in patients using GLP-1 medications…

FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness →
New York Post9 Nov

The FDA has mandated that manufacturers update warning labels on GLP-1 drugs like Ozempic and Wegovy to include a potential risk of nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can lead to permanent vision loss or blindness. This decision follows a study showing diabetes patients taking semaglutide are four times more likely to develop NAION compared to those not using the drug…

GLP-1 drugs must have new warning label over incurable blindness condition, says FDA →
Just the News10 Nov

The Food and Drug Administration will require weight loss drugs like Ozempic and Wegovy to include warnings about a rare side effect that can lead to permanent vision loss due to non-arteritic anterior ischemic optic neuropathy. This condition, which has been reported with all GLP-1 drugs used for obesity and diabetes management, can result in significant vision impairment. The FDA initiated this review following a…

Weight loss drugs, such as Ozempic, to carry FDA warning about rare vision-loss side effects →
Global News10 Nov

The FDA announced on Monday that it will require drug labels for GLP-1 medications, including Ozempic and Wegovy, to include a warning about the rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. Based on an analysis of over 125 clinical trials, the condition occurs in approximately six out of every 100,000 patients using GLP-1 drugs for at…

FDA to require vision loss warning on GLP-1 drug labels →
Show 2 more outlets
The Guardian10 Nov

The US FDA has issued a warning about GLP-1 weight loss medications, including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, and Sanofi’s Soliqua, due to the risk of nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. The FDA reviewed 126 clinical trials involving over 134,200 patients and found a higher incidence rate of NAION in GLP-1 users compared to…

FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications →
BBC10 Nov

The FDA has instructed manufacturers of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound to include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. NAION occurs when blood vessels supplying the optic nerve are blocked, leading to vision loss that may be permanent. The FDA’s decision is based on its review of reports and…

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness →

Where they agree and split

Framing

How the first headlines put it

Attributed to a source1
Stated as fact3
The headlines (4)

GLP-1 drugs must have new warning label over incurable blindness condition, says FDA New York Post · attributed to a source

US is requiring weight-loss drug makers to warn about possible loss of eye sight The Independent · stated as fact

FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness NBC News · stated as fact

FDA warns of rare vision-loss side effect from GLP-1 drugs CBS News · stated as fact

The full story: what happened, how it changed, and all 12 articles →

Compared with similar articles

This article reads unscored and hedges 16% of its claims. Each row says how that neighbour differs.
Global News
Hedges 2 of 18 claims Outlet record 63/100
The Independent
Hedges 3 of 30 claims Outlet record 59/100
The Independent
Hedges 1 of 4 claims Outlet record 59/100
The Guardian
Hedges 2 of 20 claims Outlet record 64/100
BBC News
Hedges 4 of 19 claims Outlet record 65/100
NBC News
Hedges 3 of 17 claims Outlet record 78/100
New York Post
Hedges 2 of 18 claims Outlet record 66/100
CBS News
Outlet record 66/100
CBS News
Hedges 0 of 2 claims Outlet record 66/100
Just The News
Hedges 1 of 8 claims Outlet record 59/100

Story

FDA Warns GLP-1 Drugs Eye Risk
Health · 12 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
25
sentences that state something as happening or true
Uncertain
16%
4 of 25 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
66/100
CBS News's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
12
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-10 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

CBS News · 5941 article(s) · 11 correction(s) detected
Running correction rate · 11 correction(s)

Who wrote this

Sandra Temko
1 article(s) here · 1 carrying a prediction
Popular , including Ozempic and Wegovy, will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators announced Monday.
The only article under this byline in the corpus.

Topics

FDA Mounjaro Ozempic Wegovy Zepbound

Subjects

FDA ORG · 8× CBS News ORG · 2× Lilly ORG · 2× Rizzo PERSON · 2× Joseph Rizzo PERSON · 1× Novo Nordisk ORG · 1× Novo Nordisk's ORG · 1× The Food and Drug Administration ORG · 1× U.S. GPE · 1× the American Academy of Ophthalmology ORG · 1×

Narrative

Dr. Joseph Rizzo, a neuro-ophthalmologist who co-authored that paper, told CBS News on Monday that he and his team had been working with the FDA to gather and review data on the issue for some time and that, while he didn't know the agency was ready to make a decision, he wasn't surprised it chose to add the warning.
framing: assertive · carried by 1 article(s) · first seen 2026-11-10
Popular , including Ozempic and Wegovy, will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators announced Monday.
2026-11-10 · CBS News
FDA warns of rare vision-loss side effect from GLP-1 drugs · assertive framing

Claims (25 extracted, 4 hedged)

Popular , including Ozempic and Wegovy, will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators announced Monday. asserted
regulators → include → loss
The Food and Drug Administration said the risk will be added to the labeling of all , the blockbuster medications used to treat obesity, diabetes and several other medical conditions. asserted
risk → say → obesity
The class includes a dozen injectable or pill-based drugs, including widely used brands like Zepbound and Mounjaro. asserted
class → include → Zepbound
The eye condition, known as non-arteritic anterior ischemic optic neuropathy, or NAION, can cause significant vision loss. asserted
condition → know → loss
The problem, which has been reported with all GLP-1 drugs, is caused by decreased blood flow to the optic nerve, although the underlying cause isn't understood, the FDA said. asserted
FDA → report → nerve
FDA scientists began looking into the problem after the publication of a 2024 medical paper tying the condition to certain patients taking semaglutide, the active drug in Novo Nordisk's Ozempic and Wegovy. asserted
scientists → begin → Ozempic
Dr. Joseph Rizzo, a neuro-ophthalmologist who co-authored that paper, told CBS News on Monday that he and his team had been working with the FDA to gather and review data on the issue for some time and that, while he didn't know the agency was ready to make a decision, he wasn't surprised it chose to add the warning. asserted
it → co → warning
He stressed that while he believes the evidence shows GLP-1 usage increases the risk of developing NAION, he doesn't discourage patients from taking them, saying, "The medicines have really been profoundly beneficial to a large number of people." asserted
medicines → stress → people
People who aren't on GLP-1s can also develop NAION, which affects somewhere between 2 to 10 of every 100,000 adults over age 50, according to the American Academy of Ophthalmology. uncertain
which → develop → Ophthalmology
Novo Nordisk, the and Ozempic, said it "continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines. asserted
we → say → medicines
""We recognize that NAION can have a profound impact on patients and their families," it said. asserted
it → recognize → patients
"Patient safety is a top priority for Novo, and we continue to monitor the safety of our medicines, review new research and work with health authorities around the world." asserted
we → continue → world
Eli Lilly, which makes Zepbound and Mounjaro, said in a statement Monday it was "carefully evaluating the update and will respond to FDA promptly." "Patient safety is Lilly's top priority," the company said. asserted
company → make → FDA
FDA's drug safety communication applies to all medicines with GLP-1 RA activity and does not reference any findings specific to Lilly medicines. asserted
communication → apply → medicines
An FDA analysis of more than 125 clinical trials found that the problem occurred in roughly 6 of every 100,000 patients who took a GLP-1 for at least one year. asserted
who → find → year
The comparable rate for people taking a placebo or other types of glucose-lowering medications was less than 4 per 100,000, the FDA said. asserted
FDA → take → 100,000
The agency also found reports of the problem in its electronic reporting system for drug injuries and side effects. asserted
agency → find → injuries
Symptoms of the problem include blurred vision, blind spots, distorted colors and other visual disturbances, according to the FDA. uncertain
Symptoms → include → FDA
Patients experiencing such problems should contact a health care professional immediately, the agency said. asserted
agency → experience → professional
Rizzo noted that the vision loss from the condition tends to be irreversible and can become progressively worse, even if a patient stops taking the medication. asserted
patient → note → medication
"Usually when you lose vision, although there may be some mild degree of improvement, it's usually not a large degree of improvement," he said. uncertain
he → lose → improvement
"And unfortunately, a great frustration for so many of our patients and doctors who take care of patients with NAION is the fact that we do not really know how to mitigate the risk." asserted
we → take → risk
Rizzo also said the condition does not necessarily affect each eye the same. asserted
condition → say → eye
"The degree of visual loss in the first eye does not inform the degree of visual loss that would occur in the second eye," he told CBS News. asserted
he → inform → News
"So you could have mild visual loss in one eye, and then the next eye could be severe." uncertain
eye → have → eye
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support